Characterization of .alpha.-adrenoceptor populations. Quantitative relationships between cardiovascular effects initiated at central and peripheral .alpha.-adrenoceptors

Journal of Medicinal Chemistry
1981.0

Abstract

The agonist selectivities of central (medullary) and peripheral (vascular) alpha-adrenoceptors were compared in order to investigate a possible similarity among these two alpha-adrenoceptor populations. Linear regression equations were derived between the alpha-adrenergic potencies, mediated by these two types of alpha-adrenoceptors for 21 structurally dissimilar alpha-adrenoceptor agonists. Hypotensive potency after intravenous administration to anesthetized, normotensive rats was determined as a measure of central alpha-adrenergic activity and expressed as pC25, obtained from log dose-response curves. Peripheral alpha-adrenergic potency was quantified by means of the hypertensive effect elicited in pithed, normotensive rats after intravenous injections, yielding pC60 as the biological variable. A most significant linear relationship was generated between central hypotensive activity (pC25) and peripheral hypertensive potency (pC60), provided that log P' (octanol/buffer; pH 7.4, 37 degrees C) was included into the regression in a parabolic form. This result indicates that the central (medullary) alpha-adrenoceptors and the peripheral (vascular) alpha-adrenoceptor sites, which are excited by the drugs in question, make identical demands upon their agonists. The difference in accessibility to these peripheral and central alpha-adrenoceptor populations is adequately accounted for by a parabolic description in log P'. The apparent contradiction of this finding with the suggestion that central, hypotensive alpha-adrenoceptors are of the alpha 2 type and peripheral, vascular alpha-adrenoceptors belong to the alpha 1 subpopulation is discussed. The recent identification of an additional subclass of postsynaptic, vascular alpha 2-adrenoceptors and the lack of pronounced differential stimulating activity of the agonists at peripheral alpha-adrenoceptors may explain the present findings and clarify the paradox.

Knowledge Graph

Similar Paper

Characterization of .alpha.-adrenoceptor populations. Quantitative relationships between cardiovascular effects initiated at central and peripheral .alpha.-adrenoceptors
Journal of Medicinal Chemistry 1981.0
Quantitative relationships between .alpha.-adrenergic activity and binding affinity of .alpha.-adrenoceptor agonists and antagonists
Journal of Medicinal Chemistry 1984.0
Centrally acting .alpha.1-adrenoceptor agonists based on hexahydronaphth[2,3-b]-1,4-oxazines and octahydrobenzo[g]quinolines
Journal of Medicinal Chemistry 1992.0
.alpha.- and .beta.-Adrenoceptors: From the Gene to the Clinic. 2. Structure-Activity Relationships and Therapeutic Applications
Journal of Medicinal Chemistry 1995.0
α<sub>2</sub>-Adrenoreceptors Profile Modulation. 4. From Antagonist to Agonist Behavior
Journal of Medicinal Chemistry 2008.0
Synthesis and Evaluation of 2-[(5-Methylbenz-1-ox-4-azin-6-yl)imino]imidazoline, a Potent, Peripherally Acting α<sub>2</sub>Adrenoceptor Agonist
Journal of Medicinal Chemistry 1996.0
.alpha.-Adrenergic activities of some substituted 2-(aminomethyl)imidazolines
Journal of Medicinal Chemistry 1983.0
N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-yl)-N-methyl-2-hydroxyethanesulfonamide: a potent and selective .alpha.2-adrenoceptor antagonist
Journal of Medicinal Chemistry 1985.0
1-(Alkylamino)isochromans: hypotensives with peripheral and central activities
Journal of Medicinal Chemistry 1982.0
2-Alkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor
Journal of Medicinal Chemistry 1991.0